CHRISTINE LINDSAY: Open Payments
NPI 1659865129 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$889 in 44 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $274 · 2025 $889
Food & beverage: $889
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $229 |
| ABBVIE INC. | 10 | $144 |
| Lilly USA, LLC | 6 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Averitas Pharma Inc. | 1 | $33 |
| Exact Sciences Corporation | 2 | $31 |
| PFIZER INC. | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
Products named: Ozempic, VRAYLAR, ZEPBOUND, CAPLYTA, Wegovy, QULIPTA, MOUNJARO, AIRSUPRA.
Industry payments across SC — which companies pay providers there.
